Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6056596 | 0.95 | CA1 (0.34) | CA1CA2SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL6449413 | 0.91 | FYN (0.40) | CA1CA2SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL6056612 | 0.86 | FYN (0.36) | SLC6A4SLC6A3SLC6A2GAASMN1; SMN2 | |
| SCHEMBL6449393 | 0.84 | ESR1 (0.51) | SMN1; SMN2ESR1ESR2 | |
| SCHEMBL6451799 | 0.83 | ESR1 (0.43) | HSP90AA1HSP90AB1ESR1ESR2 | |
| SCHEMBL6056626 | 0.80 | CA1 (0.37) | CA1CA2SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL6056663 | 0.79 | ESR1 (0.38) | CA1CA2SLC6A4SLC6A3GAA | |
| SCHEMBL6448253 | 0.79 | ESR1 (0.42) | HSP90AA1HSP90AB1ESR1ESR2TSHR | |
| SCHEMBL6450658 | 0.79 | ESR1 (0.42) | SLC6A4SLC6A3SLC6A2ESR1ESR2 | |
| SCHEMBL6450675 | 0.78 | GABRA1 (0.43) | GAAESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050148570-A1 | Novel substituted alkane compounds and uses thereof | HUANG LIREN (US) | 2005-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148570-A1 | Novel substituted alkane compounds and uses thereof | ALK, CYP11B2, ALKBH2 | CA1 2184/4885CA2 2113/4885SLC6A4 2174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.